First slide
Cytocell Logo

Product summary

  • Technology FISH
  • Application Haematology
  • Areas of interest AML, MDS
  • Region 3q26.2
  • Label      
  • Product No. LPH 036 (10 tests)
    LPH 036-S (5 tests)
  • Intended use In vitro diagnostic. This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples. Disease information supported by the literature and is not a reflection of the intended purpose of this product.

Chromomaps

Overview

Probe specification

  • EVI1, 3q26.2, Red
  • EVI1, 3q26.2, Green
  • EVI1, 3q26.2, Blue

The red component of the EVI1 probe mix consists of a 158kb probe telomeric to the D3S4415 marker and includes the LRRC34 gene. The green component covers a 181kb region that includes the centromeric part of the EVI1 (MECOM) gene and beyond marker D3S1282. The blue component covers a 563kb region centromeric to the EVI1 gene, that includes the D3S1614 marker.

 

Probe information

The MECOM (MDS1 and EVI1 complex locus) oncogene at 3q26.2 is often rearranged in haematological malignancies of myeloid origin.

MECOM encodes a zinc finger protein that is inappropriately expressed in the leukaemic cells of between 2-5% of AML and MDS patients1. This deregulated expression is often due to a chromosomal rearrangement involving 3q26.2, with the two most common aberrations being the t(3;3)(q21;q26.2) and inv(3)(q21q26.2)1. The breakpoints for the translocations and inversions vary considerably.

Inversion breakpoints are found centromeric to, and including, the MECOM gene and cover about 600kb. The majority of breakpoints in 3q26.2 translocations are telomeric to the MECOM gene and cover a region including the telomeric end of the MDS1 gene and the MYNN gene2.

Chromosome rearrangements involving the 3q26.2 region are associated with myeloid malignancies, aberrant expression of MECOM gene, an unfavourable prognosis and an aggressive clinical course2.

AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) is a recognised disease entity according to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukaemia. This is a transformed or de novo AML with a very aggressive clinical course and aberrations that involve MECOM at 3q26.2 and RPN1 (ribophorin I) at 3q213.

MECOM has also been shown to be rearranged in therapy-related disease via the t(3;21)(q26.2;q22) translocation, resulting in a MECOM- RUNX1 fusion3,4.

MECOM rearrangements are very heterogeneous and may be difficult to detect by conventional cytogenetics, making FISH a useful tool for their detection.

What our customers say

References

  1. Soderholm et al., Leukemia 1997;11:352-358
  2. Bobadilla et al., Br J Haematol 2007;136:806-813
  3. Swerdlow et al., (eds,) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, Lyon, France, 4th edition, IARC,2017
  4. Pedersen-Bjergaard et al., Leukemia 2008;22:240-248

Recommended protocol for CytoCell haematology FISH

Select a protocol step to view:

Sample and slide preparation

Sample and slide preparation Thumbnail
  • Spot the cell sample onto a glass microscope slide. Allow to dry.
  • Immerse the slide in 2x Saline Sodium Citrate (SSC) for 2 minutes at room temperature (RT) without agitation.
  • Dehydrate in an ethanol series (70%, 85% and 100%), each for 2 minutes at RT.
  • Allow to dry.
Haematology FISH protocol Video Image
Play Icon

Haematology FISH protocol

Request a quote for this product

FISH resources & support